Advanced glycation end products in human cancer tissues: Detection of Nε-(carboxymethyl)lysine and argpyrimidine

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 725-733

  Van Heijst, Jeroen W J ^a   Niessen, Hans W M ^a   Hoekman, Klaas ^a   Schalkwijk, Casper G ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ANTIBODY; ARGININE DERIVATIVE; ARGPYRIMIDINE; GLUCOSE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

BREAST ADENOCARCINOMA; CANCER TISSUE; CARCINOGENESIS; COLON ADENOCARCINOMA; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; LEIOMYOSARCOMA; SQUAMOUS CELL CARCINOMA;

EID: 23744454602     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.084     Document Type: Conference Paper

References (26)

1. SHINOHARA, M. et al. 1998. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation end product formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J. Clin. Invest. 101: 1142-1147.
2. REDDY, S. et al. 1995. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878.
3. KISLINGER, T. et al. 1999. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274: 31740-31749.
4. OYA, T. et al. 1999. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal-arginine adducts. J. Biol. Chem. 274: 18492-18502.
5. SHAMSI, F.A. et al. 1998. Immunological evidence for methylglyoxal- derived modifications in vivo. Determination of antigenic epitopes. J. Biol. Chem. 273: 6928-6936.
6. VITEK, M.P. et al. 1994. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91: 4766-4770.
7. VLASSARA, H., H. FUH, T. DONNELLY & M. CYBULSKY. 1995. Advanced glycation end products promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol. Med. 1: 447-456.
8. IMAI, N. et al. 1997. Histological localization of advanced glycosylation end products in the progression of diabetic nephropathy. Nephron 76: 153-160.
9. SCHALKWIJK, C.G. et al. 2004. Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. Biochim. Biophys. Acta 1636: 82-89.
10. HSIEH, H.L., B.W. SCHAFER, N. SASAKI & C.W. HEIZMANN. 2003. Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem. Biophys. Res. Commun. 307: 375-381.
11. SHIPANOVA, I.N., M.A. GLOMB & R.H. NAGARAJ. 1997. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct. Arch. Biochem. Biophys. 344: 29-36.
12. TEERLINK, T., R. BARTO, H.J. TEN BRINK & C.G. SCHALKWIJK. 2004. Measurement of Nepsilon-(carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry. Clin. Chem. 50: 1222-1228.
13. AHMED, N. et al. 2002. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxy-succinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin. Biochem. J. 364: 1-14.
14. UESUGI, N. et al. 2001. Glycoxidation-modified macrophages and lipid peroxidation products are associated with the progression of human diabetic nephropathy. Am. J. Kidney Dis. 38: 1016-1025.
15. OKAMOTO, T. et al. 2002. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 16: 1928-1930.
16. SCHMIDT, A.M. et al. 1995. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest 96: 1395-1403.
17. KISLINGER, T. et al. 2001. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21: 905-910.
18. YAN, S.D. et al. 1994. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897.
19. STOPPER, H., R. SCHINZEL, K. SEBEKOVA & A. HEIDLAND. 2003. Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett. 190: 151-156.
20. KUNIYASU, H. et al. 2002. Expression of receptors for advanced glycation end products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol. 196: 163-170.
21. OKAMOTO, T. et al. 2002. Advanced glycation end products induce angiogenesis in vivo. Microvasc. Res. 63: 186-195.
22. YAMAGISHI, S. et al. 1997. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272: 8723-8730.
23. KUZUYA, M. et al. 1998. Inhibition of angiogenesis on glycated collagen lattices. Diabetologia 41: 491-499.
24. PAPOULIS, A., Y. AL ABED & R. BUCALA. 1995. Identification of N2-(1-carboxyethyl)guanine (CEG) as a guanine advanced glycosylation end product. Biochemistry 34: 648-655.
25. ROBERTS, M.J. et al. 2003. DNA damage by carbonyl stress in human skin cells. Mutat. Res. 522: 45-56.
26. SAKAMOTO, H., T. MASHIMA, K. YAMAMOTO & T. TSURUO. 2002. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J. Biol. Chem. 277: 45770-45775.